ArticlePediatric pulmonology2025
Are EQ-5D-Y-3L and EQ-5D-Y-5L Useful Tools to Assess Health Outcomes in Children With Asthma? An Analysis of Child and Parental Carer Reporting.
Article in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of Allergen-Specific Subcutaneous Immunotherapy on 12-Month Health-Related Quality of Life in Children and Their Parental Caregivers.Allergy, asthma & immunology research · 2026Article
- Trade-offs from a family perspective: considerations in choosing between omalizumab and complementary alternative medicine for pediatric severe asthma.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe three-level and five-level child-friendly versions (EQ-5D-Y) are widely employed for assessing health-related quality of life (HRQoL) in children. However, their effectiveness in asthma remains understudied. We aimed to assess their psychometric properties in asthmatic children.
methodsSeventy-six dyads of patients and their parents completed EQ-5D-Y-5L and EQ-5D-Y-3L, respectively, at two visits. Test-retest reliability and patient-caregiver agreement were assessed using intraclass correlation coefficient (ICC). Known-groups validity was assessed by comparing scores across varying asthma control levels. Responsiveness was assessed in children showing improved overall health and asthma control.
resultsICCs for test-retest reliability of EQ-5D-Y-3L and EQ-5D-Y-5L summary scores ranged from 0.744 to 0.898 (self-report) and 0.525 to 0.767 (proxy-report), indicating satisfactory reliability. As expected, EQ-5D-Y summary scores for both versions were better in well- or partially-controlled patients, with fewer problems reported for each dimension as well. Effect sizes ranged from 0.19 to 1.00 for the self-completed version, from 0.39 to 0.83 for the proxy version, and from 0.26 to 1.40 for EQ VAS in patients showing improvement. Patient-caregiver agreement ranged from moderate to good.
conclusionThe results support the use of the self-complete and proxy versions of both EQ-5D-Y-3L and EQ-5D-Y-5L to assess health outcomes in children with asthma. The self-complete EQ-5D-Y-3L is preferred where possible, but parental carer reports can be used as a reasonable proxy when necessary. The EQ VAS offers a valuable complementary perspective on overall health. Further investigation of the EQ-5D-Y-5L is recommended once a value set becomes available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.